Santen Pharmaceutical Co Ltd (SNPHF)
OTHER OTC:SNPHF
SNPHF Stock Chart & Stats
$10.60
$0.00(0.00%)
At close: 4:00 PM EST
$10.60
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$8.69 - $13.65
Previous CloseN/A
Volume1.00K
Average Volume (3M)0.00
Market Cap
$3.68B
Enterprise Value$562.14B
Total Cash (Recent Filing)$61.54B
Total Debt (Recent Filing)$36.15B
Price to Earnings (P/E)16.7
Beta-0.05
Next Earnings
May 12, 2026EPS Estimate
0.2Next Dividend Ex-DateN/A
Dividend Yield2.47%
Share Statistics
EPS (TTM)0.15
Shares Outstanding322,273,960
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.32
Price to Book (P/B)1.73
Price to Sales (P/S)1.65
P/FCF Ratio9.11
Enterprise Value/Market Cap152.71
Enterprise Value/Revenue1.95
Enterprise Value/Gross Profit3.63
Enterprise Value/Ebitda9.45
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.73
Revenue Forecast (FY)$1.87B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetSanten's very low debt-to-equity (around 0.10–0.13) and large equity base provide durable financial flexibility. This conservative capital structure supports continued R&D and manufacturing investment, smooths funding for launches, and reduces refinancing risk over the next several months.
Profitability ReboundThe company returned to consistent profitability after 2023, with TTM net margin above 10%. This rebound indicates improved cost control and earnings power, strengthening the firm's ability to fund product lifecycle activities and sustain margins despite cyclical pressures.
Strong Cash ConversionFree cash flow that closely tracks net income (~85–89%) signals high earnings quality and reliable cash generation. That conversion supports reinvestment, dividend capacity, and strategic flexibility even if revenue growth is soft, sustaining operations over the medium term.
Bears Say
Declining RevenueRevenue has declined (roughly -4.6% in the provided metric) and the income statement notes softer top-line trends. Persistent revenue contraction can erode scale, reduce pricing power in regulated markets, and limit resources for new launches or geographic rollouts if not reversed.
Weakened Cash Flow MomentumOperating cash flow and free cash flow have stepped down in the TTM, suggesting higher working-capital needs or elevated investment spending. Reduced cash momentum raises execution risk for launches, lifecycle investments, and shareholder returns if weaker cash persists.
Shrinking Equity And AssetsA declining equity and asset base from 2022 levels narrows the balance-sheet cushion. That reduction limits borrowing capacity and financial flexibility to absorb further revenue weakness or fund opportunistic M&A and could force tougher trade-offs if headwinds continue.
Santen Pharmaceutical Co News
SNPHF FAQ
What was Santen Pharmaceutical Co Ltd’s price range in the past 12 months?
Santen Pharmaceutical Co Ltd lowest stock price was $8.69 and its highest was $13.65 in the past 12 months.
What is Santen Pharmaceutical Co Ltd’s market cap?
Santen Pharmaceutical Co Ltd’s market cap is $3.68B.
When is Santen Pharmaceutical Co Ltd’s upcoming earnings report date?
Santen Pharmaceutical Co Ltd’s upcoming earnings report date is May 12, 2026 which is in 29 days.
How were Santen Pharmaceutical Co Ltd’s earnings last quarter?
Santen Pharmaceutical Co Ltd released its earnings results on Feb 05, 2026. The company reported $0.153 earnings per share for the quarter, missing the consensus estimate of $0.183 by -$0.031.
Is Santen Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Santen Pharmaceutical Co Ltd’s price is currently Overvalued.
Does Santen Pharmaceutical Co Ltd pay dividends?
Santen Pharmaceutical Co Ltd pays a Semiannually dividend of $0.123 which represents an annual dividend yield of 2.47%. See more information on Santen Pharmaceutical Co Ltd dividends here
What is Santen Pharmaceutical Co Ltd’s EPS estimate?
Santen Pharmaceutical Co Ltd’s EPS estimate is 0.2.
How many shares outstanding does Santen Pharmaceutical Co Ltd have?
Santen Pharmaceutical Co Ltd has 322,273,960 shares outstanding.
What happened to Santen Pharmaceutical Co Ltd’s price movement after its last earnings report?
Santen Pharmaceutical Co Ltd reported an EPS of $0.153 in its last earnings report, missing expectations of $0.183. Following the earnings report the stock price went up 0.225%.
Which hedge fund is a major shareholder of Santen Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in SNPHF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Santen Pharmaceutical Co Ltd
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.
Technical Analysis
Astellas Pharma
―
Menicon Co
―
Nipro
―
Tsubota Laboratory Incorporated
―
Japan Eyewear Holdings Co.,Ltd.
―
Ownership Overview
―
Insiders
6.30% Mutual Funds
― Other Institutional Investors
86.20% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---